For Immediate Release: Nov. 2, 2006      
       Contact: Laurie Fink: (301) 841-2602;
                       Thai Phi Stone: (301) 907-2593;

Denver to Host Largest Gathering of Cystic Fibrosis Scientists and Clinicians in the World

People with cystic fibrosis living to median age of nearly 37 due to advances in research and care

(Denver) — In the largest meeting of its kind, more than 3,000 doctors, scientists, researchers and caregivers will meet in Denver Nov. 2 – 5, 2006, to present the latest information and advancements on cystic fibrosis (CF) care, drug research and trends—from the laboratory to the clinic setting. The North American Cystic Fibrosis Conference (NACFC) provides a unique opportunity for cystic fibrosis experts from every field of science and medicine to receive cutting-edge information about what is happening in the field and how it can affect their work and their patients. The NACFC meeting, in its 20th year, has helped to significantly advance CF research, understanding of the disease and the search for a cure.

Fifty years ago, children with CF did not live long enough to attend elementary school. Today, because of Cystic Fibrosis Foundation-supported drug research and care, patients in the United States are living to a median age of nearly 37. CF is one of the most common life-threatening genetic diseases in this country. It affects about 30,000 people nationwide, and 10 million people are unknowing carriers of one of the CF genes.

The 20th Annual North American Cystic Fibrosis Conference, the largest international gathering of leading cystic fibrosis scientists, researchers and clinicians.

Thursday, Nov. 2 – Sunday, Nov. 5, 2006 at the Colorado Convention Center, Denver


  • Denver-area families who have children or other family members with cystic fibrosis.
  • Leading scientists and clinicians at the meeting.


  • Friday, Nov. 3, 8:30 a.m. – “Promises to Keep: Turning Discoveries into Drugs.” Highlighting groundbreaking research of the last year. Pamela B. Davis, M.D., Ph.D., Case Western Reserve University, Cleveland, Ohio.

  • Saturday, Nov. 4, 9:00 a.m. – “Clinical Research: Our Compass to a Cure.” Highlighting efforts to apply new CF therapies aimed at correcting the genetic defect and how to measure their effectiveness. J.P. Clancy, M.D., University of Alabama, Birmingham. 

  • Sunday, Nov. 5, 7:45 a.m. – “CF Pulmonary Care: Measuring & Improving Our Effectiveness.” Highlighting advances in pulmonary care with a focus on currently available therapies and approaches. James R. Yankaskas, M.D., University of North Carolina, Chapel Hill.

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the leading organization in the United States devoted to cystic fibrosis, a life-threatening genetic disease that affects about 30,000 people nationwide. The CF Foundation has more than 80 chapters and fund-raising offices nationwide and supports a network of more than 115 Foundation-accredited CF care centers, which provide patients and families with vital treatment and other CF resources.

Based in Bethesda, Md., the CF Foundation is one of the most efficient organizations of its kind. In 2005, nearly 90 percent of every dollar of revenue raised was available for investment in CF research, care and education programs. The National Institutes of Health and many prominent publications, including Forbes and USA Today, have heralded the Foundation’s innovative business model, which fuels drug discovery and development programs.